End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.67 CNY | +0.13% | -1.92% | -4.12% |
06-20 | Haier Gets Regulatory Nod to Buy Controlling Stake in RAAS Blood Products | MT |
06-19 | RAAS Blood Products Renews Cooperation Deal With Spain's Grifols | MT |
Business Summary
China accounts for 96.6% of net sales.
Number of employees: 3,254
Sales per Business
CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Albumin - Imported
44.0
%
| 2,734 | 41.6 % | 3,504 | 44.0 % | +28.16% |
Intravenous Injection
22.7
%
| 1,313 | 20.0 % | 1,805 | 22.7 % | +37.47% |
Albumin - Self-produced
18.0
%
| 1,489 | 22.7 % | 1,431 | 18.0 % | -3.94% |
Other Blood Products
13.6
%
| 968 | 14.7 % | 1,081 | 13.6 % | +11.68% |
Testing Equipment and Reagents
1.8
%
| 61 | 0.9 % | 141 | 1.8 % | +131.25% |
Other Business
0.0
%
| 1 | 0.0 % | 2 | 0.0 % | +19.10% |
Sales per region
CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
100.0
%
| 6,567 | 100.0 % | 7,964 | 100.0 % | +21.27% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jun Xu
CEO | Chief Executive Officer | 60 | 11-12-31 |
Le Qi Chen
DFI | Director of Finance/CFO | 37 | 21-10-25 |
Wei Bing Hu
CHM | Chairman | 60 | 03-03-02 |
Hong Qiu
IRC | Investor Relations Contact | - | - |
Ji Hui Chen
PRN | Corporate Officer/Principal | 58 | 04-04-30 |
Hui Lu
PRN | Corporate Officer/Principal | 49 | 09-04-30 |
Zheng Liu
SEC | Corporate Secretary | 54 | 07-04-26 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 20-05-19 | |
Yue Wen Zheng
BRD | Director/Board Member | 62 | 07-04-26 |
David Bell
BRD | Director/Board Member | 70 | 20-05-19 |
Ya Min Chen
BRD | Director/Board Member | 72 | 22-06-13 |
Director/Board Member | 57 | 20-05-20 | |
Binh Hoang
BRD | Director/Board Member | 50 | 07-04-26 |
Jun Xu
CEO | Chief Executive Officer | 60 | 11-12-31 |
Wei Bing Hu
CHM | Chairman | 60 | 03-03-02 |
Ling Peng
BRD | Director/Board Member | 45 | 20-05-19 |
Bing Yu Wang
BRD | Director/Board Member | 58 | 22-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,645,480,758 | 4,622,269,779 ( 69.56 %) | 9,495,921 ( 0.1429 %) | 69.56 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
39,960,800 | 1.87% | 82,690,883 $ |
Company contact information
Shanghai RAAS Blood Products Co., Ltd.
2009 Wangyuan Road Biotechnology Park
201401, Shanghai
+
http://www.raas-corp.comSector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.12% | 6.96B | |
+4.57% | 96.72B | |
+5.66% | 41.43B | |
-12.80% | 32.7B | |
+80.99% | 29.06B | |
-15.53% | 15.38B | |
-8.70% | 12.97B | |
-12.22% | 11.36B | |
+183.25% | 9.9B | |
+3.60% | 8.93B |
- Stock Market
- Equities
- 002252 Stock
- Company Shanghai RAAS Blood Products Co., Ltd.